Cancer immunotherapy with immune checkpoint blockade (ICB) targeting programmed cell death protein 1 (PD-1) or cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) has revolutionized cancer treatment in different malignancies [1]. Here, CTLA4 is linked to cancer.